{"id":"fondaparinux-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201202","moleculeType":"Oligosaccharide","molecularWeight":"1508.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fondaparinux is a pentasaccharide that binds to antithrombin III, enhancing its ability to inactivate Factor Xa in the coagulation cascade. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby inhibiting clot formation without directly affecting thrombin itself. This selective mechanism provides anticoagulation with a predictable pharmacokinetic profile.","oneSentence":"Fondaparinux is a synthetic anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:16.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis in orthopedic surgery"},{"name":"Acute deep vein thrombosis treatment"},{"name":"Acute pulmonary embolism treatment"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT01727401","phase":"PHASE4","title":"Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia","status":"TERMINATED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Medical Patient, Thrombocytopenia","enrollment":7},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT01420809","phase":"","title":"Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Thromboembolism","enrollment":1280},{"nctId":"NCT01444612","phase":"","title":"Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02","conditions":"Thrombosis, Venous","enrollment":4068}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fondaparinux Injectable Product","genericName":"Fondaparinux Injectable Product","companyName":"Queen Mary University of London","companyId":"queen-mary-university-of-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fondaparinux is a synthetic anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and blood clot formation. Used for Venous thromboembolism prophylaxis in orthopedic surgery, Acute deep vein thrombosis treatment, Acute pulmonary embolism treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}